Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedlineMDLN -1.21%17 EV-to-EBITDA is 16.62 as of Aug. 11, 2026, which is 5% below its 10-year median of 17.58. GuruFocus rates MDLN with a GF Score™ of 17/100. The stock has 3 warning signs investors should review. Among 516 Medical Devices & Instruments companies, Medline ranks worse than 56.01% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Medline's enterprise value is $46,763 Mil.
Medline's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $2,813 Mil. Therefore, Medline's EV-to-EBITDA for today is 16.62.
The historical rank and industry rank for Medline's EV-to-EBITDA or its related term are showing as below:
MDLN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 15.32 Med: 17.58 Max: 29.47
Current: 16.62
During the past 4 years, the highest EV-to-EBITDA of Medline was 29.47. The lowest was 15.32. And the median was 17.58.
MDLN's EV-to-EBITDA is ranked worse than 56.01% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 14.81
vs MDLN: 16.62
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medline's share price for today is $33.39.
Medline's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.396.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Medline's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Medline's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medline EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medline's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medline's EV-to-EBITDA falls into.
Medline's current Enterprise Value is $46,763 Mil.
Medline's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,813 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medline (MDLN) has a EV-to-EBITDA of 16.62 as of Aug. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medline. This is near median its historical median of 17.58. Over the past decade, Medline's EV-to-EBITDA has ranged from 15.32 to 29.47. According to the industry distribution chart, Medline ranks #289 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 56%.
Is Medline's EV-to-EBITDA too high?
Medline's current EV-to-EBITDA of 16.62 is near median its 10-year median of 17.58. Over the past 10 years, this metric has ranged from a low of 15.32 to a high of 29.47. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.81. Medline's value of 16.62 is 12.2% above this industry median. Based on the distribution chart, Medline ranks #289 out of 516 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Medline has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Medline's EV-to-EBITDA compare to RMD and WST?
According to the Medical Devices & Instruments industry distribution chart, Medline ranks #289 out of 516 companies for EV-to-EBITDA. This places Medline in the lower half of its industry. The industry median EV-to-EBITDA is 14.81. Medline's value of 16.62 is 12.2% above this benchmark. Historically, Medline's own EV-to-EBITDA has ranged from 15.32 to 29.47 over the past decade. While the company's 10-year median is 17.58 vs. the industry median of 14.81, Medline has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.81, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medline's current EV-to-EBITDA of 16.62 is 12.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medline. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medline's current EV-to-EBITDA is 16.62, which is near median its own 10-year median of 17.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medline stock overvalued right now?
Medline (MDLN) has a current EV-to-EBITDA of 16.62. The current EV-to-EBITDA is 16.62, which is near median its 10-year median of 17.58 and 12.2% above the Medical Devices & Instruments industry median of 14.81. Medline's overall GF Score™ is 17/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Medline (MDLN), the current EV-to-EBITDA is 16.62 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medline is the largest provider of medical-surgical products and supply chain solutions in the US. The company generates over 90% of its revenue domestically and serves some of the largest US health systems. Medline offers approximately 190,000 Medline-branded products across more than 250 product families—including front-line care, surgical solutions, and laboratory and diagnostics—as well as roughly 150,000 third-party products sourced from over 1,250 vendors. The company maintains prime vendor relationships with many customers, acting as the primary consolidated logistics partner for their medical-surgical needs. Medline has significant scale, supported by more than 30 manufacturing facilities and a fleet of over 2,000 owned delivery trucks. Medline went public in December 2025.
17GF Score
Get the complete analysis for MDLN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDLN has been successfully added to your 
